Anaesthesia
-
McCombe and Bogod report on their analysis of 55 medicolegal claims relating to obstetric neuraxial anaesthesia and analgesia.
Why is this important?
Not only is neurological injury the second most common reason for obstetric anaesthetic claims (behind inadequate regional anaesthesia resulting in pain during Caesarean section), the average claim cost is greater.
McCombe and Bogod provide a factful exploration of many of the causes of neurological complications.
Which themes emerged from their analysis?
- Consent, particularly around providing inadequate pre-procedure information of the risk of neurological injury1 and the challenges, medical and legal, to achieving informed consent.
- Nerve injury and it's mechanisms: non-anaesthetic causes2, direct trauma, chemical, and compression (abscess, haematoma).
- Complication recognition & management means timely follow-up and assessment, and maintaining a high index of suspicion for abnormalities. Remember the 4 hour rule: blocks should be regressing 4 hours after the last dose.
Important reminders
The level of spinal cord termination varies a lot among individuals, as does the level of Tuffier's line3. Considering the inaccuracy of spinal level identification by anaesthetists, there is a lot of potential to place a needle higher than expected.
Bottom-line: the intrathecal space should be accessed at the lowest possible level, and "the L2/3 interspace should not be an option."
And never allow chlorhexidine to contaminate gloves, the sterile workspace or neuraxial equipment.
summary
-
Noting from NAP3 the risk of nerve injury ranges from, temporary injury 1:1,000, prolonged (>6 months) 1:13,000, to severe (including paralysis) 1:250,000. ↩
-
'Obstetric palsy' (pelvic nerve compression) estimated by Bromage as occurring in 1:3000 deliveries; arterial obstruction & ischaemia 1:15,000; AV malformations 1:20,000. A prospective French study found postpartum neuropathy in 0.3%, 84% were femoral, and 69% resolved at 6 weeks. ↩
-
Although generally accepted as being at the L4/5 interspace, in up to 50% of people the intercristal line might be at or above L2/3! ↩
-
Randomized Controlled Trial Comparative Study
A randomised controlled trial of shoulder block vs. interscalene brachial plexus block for ventilatory function after shoulder arthroscopy.
The shoulder block may impair ventilatory function and diaphragmatic movement less than the interscalene brachial plexus block. We randomly allocated 30 adults who underwent shoulder arthroscopy under general anaesthesia to ultrasound-guided shoulder block or interscalene block with 20 ml bupivacaine 0.5%. ⋯ The mean (SD) numeric rating scale pain scores at rest after shoulder block were higher than after interscalene block at two postoperative hours, 1.4 (1.2) vs. 0.3 (0.7), p = 0.02, but lower at 24 postoperative hours, 1.3 (1.3) vs. 3.4 (2.3), p = 0.008. Mean (SD) pain scores on movement in the shoulder and interscalene blocks were similar, with respective values of 1.9 (1.9) vs. 0.7 (1.2), p = 0.13 at two postoperative hours and 3.7 (2.3) vs. 5.3 (2.5), p = 0.41, at 24 postoperative hours.
-
Randomized Controlled Trial Comparative Study
Hemidiaphragmatic paralysis following ultrasound-guided anterior vs. posterior suprascapular nerve block: a double-blind, randomised control trial.
Interscalene brachial plexus block provides analgesia for shoulder surgery but is associated with hemidiaphragmatic paralysis. Before considering a combined suprascapular and axillary nerve block as an alternative to interscalene brachial plexus block, evaluation of the incidence of diaphragmatic dysfunction according to the approach to the suprascapular nerve is necessary. We randomly allocated 84 patients undergoing arthroscopic shoulder surgery to an anterior or a posterior approach to the suprascapular nerve block combined with an axillary nerve block using 10 ml ropivacaine 0.375% for each nerve. ⋯ The median (interquartile range [range]) oral morphine equivalent consumption was significantly higher in the posterior approach when compared with the anterior approach, whether in the recovery area (20 [5-31 (0-60)] mg vs. 7.5 [0-14 (0-52)] mg, respectively; p = 0.004) or during the first 24 h (82 [61-127 (12-360) mg] vs. 58 [30-86 (0-160)] mg, respectively; p = 0.01). Patient satisfaction was comparable between groups (p = 0.6). Compared with the anterior approach, diaphragmatic function is best preserved with the posterior needle approach to the suprascapular nerve block.
-
The cost effectiveness of reusable vs. single-use flexible bronchoscopy in the peri-operative setting has yet to be determined. We therefore aimed to determine this and hypothesised that single-use flexible bronchoscopes are cost effective compared with reusable flexible bronchoscopes. We conducted a systematic review of the literature, seeking all reports of cross-contamination or infection following reusable bronchoscope use in any clinical setting. ⋯ The cost per use of a single-use flexible bronchoscope was £220 sterling. The cost effectiveness analysis demonstrated that reusable flexible bronchoscopes have a cost per patient use of £511 sterling due to the costs of treatment of infection. The findings from this study suggest benefits from the use of single-use flexible bronchoscopes in terms of cost effectiveness, cross-contamination and resource utilisation.
-
Observational Study
Red blood cell transfusion in surgery: an observational study of the trends in the USA from 2011 to 2016.
Guidelines recommend restrictive red blood cell transfusion strategies. We conducted an observational study to examine whether the rate of peri-operative red blood cell transfusion in the USA had declined during the period from 01 January 2011 to 31 December 2016. We included 4,273,168 patients from all surgical subspecialties. ⋯ Compared with 2011, the adjusted hazard ratios (95%CI) in 2012 and 2016 were 0.96 (0.90-1.02) and 1.05 (0.99-1.11) for myocardial infarction, 0.91 (0.83-0.99) and 0.99 (0.92-1.07) for stroke and 0.98 (0.94-1.02) and 0.99 (0.96-1.03) for all-cause mortality. Use of peri-operative red blood cell transfusion declined from 2011 to 2016. This was not associated with an increase in adverse clinical outcomes.